The estimated Net Worth of Scott M. Plesha is at least 4.06 百万$ dollars as of 27 January 2022. Mr. Plesha owns over 45,253 units of Biodelivery Sciences International stock worth over 1,929,260$ and over the last 7 years he sold BDSI stock worth over 623,850$. In addition, he makes 1,503,860$ as President、 Chief Commercial Officer at Biodelivery Sciences International.
Scott has made over 14 trades of the Biodelivery Sciences International stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 45,253 units of BDSI stock worth 252,964$ on 27 January 2022.
The largest trade he's ever made was selling 50,000 units of Biodelivery Sciences International stock on 11 December 2019 worth over 318,000$. On average, Scott trades about 16,753 units every 71 days since 2018. As of 27 January 2022 he still owns at least 345,127 units of Biodelivery Sciences International stock.
You can see the complete history of Mr. Plesha stock trades at the bottom of the page.
Scott M. Plesha is the President, Chief Commercial Officer of the Company. Mr. Plesha assumed the additional responsibility of leading our Marketing department in December 2015. In January 2018, Mr. Plesha was appointed to the role of President of the Company. Mr. Plesha leads our Specialty Sales Force, Marketing, and Training departments. Prior to joining the company, Mr. Plesha was Senior Vice President, GI Sales Force & Training at Salix Pharmaceuticals, where since 2002 he led Salix’s top rated gastrointestinal (GI) sales forces, the sales training department as well as many other sales operations functions. During Mr. Plesha’s tenure at Salix he was responsible for launching or growing product sales as well as optimizing and expanding the sales force to accommodate the multiple companies and products that Salix acquired. Prior to joining Salix, Mr. Plesha was a Regional Sales Manager for the O’Classen Dermatologics division of Watson Pharmaceuticals, Inc. Mr. Plesha began his pharmaceutical sales career with Solvay Pharmaceuticals where he was a field as well institutional sales representative. Mr. Plesha received a Bachelor of Arts in Pre-Medical Studies from DePauw University.
As the President、 Chief Commercial Officer of Biodelivery Sciences International, the total compensation of Scott Plesha at Biodelivery Sciences International is 1,503,860$. There are no executives at Biodelivery Sciences International getting paid more.
Scott Plesha is 55, he's been the President、 Chief Commercial Officer of Biodelivery Sciences International since 2018. There are 9 older and 5 younger executives at Biodelivery Sciences International. The oldest executive at Biodelivery Sciences International is William Watson, 69, who is the Independent Director.
Scott's mailing address filed with the SEC is 4131 Parklake Ave #225, Raleigh, NC 27612, USA.
Over the last 20 years, insiders at Biodelivery Sciences International have traded over 111,671,776$ worth of Biodelivery Sciences International stock and bought 1,813,177 units worth 5,352,510$ . The most active insiders traders include International, L.P. Elliott、Associates, L.P. Elliott、Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of 420,648$. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth 29,811$.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: